Company intelligence / Profile preview

OnKure Therapeutics

Boulder, Colorado, United Statesonkuretherapeutics.com ↗

Ownership: Public · OKUR
Development stage: Phase 1

Overview

Preliminary safety, tolerability, and pharmacokinetic data from the first-in-human PIKture‑01 trial of OKI‑219 have been encouraging as of December 2024. The company has sufficient cash runway into Q4–2026 and continues to advance its lead candidate through early clinical development.[2]

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

9 assets

mavodelpar

8 more assets in the full pipeline.

Request access →

Partnerships

Investors include Acorn Bioventures, Cormorant Asset Management, Deep Track Capital, Perceptive Advisors, Samsara BioCapital, Surveyor Capital (Citadel), Vestal Point Capital.[5][7]

Financials

Market cap: $26.9M
Total revenue: $0
Enterprise value: $-68.8M

Beyond the preview

Go deeper on OnKure Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OnKure Therapeutics.

Explore the full profile